Podcasts about cme

Crypto News: Blackrock continues to buy huge amounts of Bitcoin for its ETF IBIT. Ethereum traders targeting $6K price. XRP futures day one beats solana's on CME.Show Sponsor -

Clinical investigators discuss available data guiding the management of pancreatic cancer.  CME information and select publications here.

Clinical investigators discuss available data guiding the management of pancreatic cancer.  CME information and select publications here.

The CME's 13th birthday is this month, and you know what that means: It's pledge month! Now through June 1, GET 50% OFF A NEW MONTHLY OR ANNUAL PATREON SUBSCRIPTION when you use the code CME13 at checkout! Get on it! Join the team! Support the community! Stick it to the man! First you've got Jon Jones riding on the back of a motorbike looking zooted out of his gourd over there in Thailand. Then you've got Jones riding his own motorbike, saying he's “living his best life” on Instagram Live while zigzagging around parked cars. Now you've got Jones replying to random dudes on Twitter (like he does) about how much he doesn't care about potentially getting stripped of the UFC heavyweight title (sure, Jon), and declaring he “told the UFC about his plans” a long time ago. All Jones cares about now, he says, is monetizing the brand he's built — which … I mean … isn't the Jon Jones Brand shooting your gun off outside the strip club and having car wrecks with pregnant ladies? How exactly is he “monetizing” that “brand” from the back of a motorbike in Thailand? Plus, everybody's washed at welterweight all of a sudden, and Ilia Topuria parts ways with his longtime coaches and trainers … WAIT, WHAT? Learn more about your ad choices. Visit megaphone.fm/adchoices

Crypto News: The Stablecoin Bill Genius Act gets vote to move to the next phase in Senate. JPMorgan to allow clients to buy Bitcoin, CEO Jamie Dimon says. Singapore dollar-pegged stablecoin gets launched on the XRP ledger.Show Sponsor -

Dr Jennifer Crombie from the Dana-Farber Cancer Institute in Boston, Massachusetts, reviews available and investigational CD20 x CD3 targeted bispecific antibodies for the treatment of follicular and diffuse large B-cell lymphomas. CME information and select publications here.

In this episode of Bowel Sounds, hosts Dr. Jenn Lee and Dr. Peter Lu  talk with Dr. Nishant Patel, pediatric gastroenterologist at Orlando Health Arnold Palmer Hospital for Children, about the diagnosis and evaluation of exocrine pancreatic insufficiency (EPI) in children. Learning objectivesRecognize the varied clinical presentations of exocrine pancreatic insufficiency (EPI)Compare the utility, advantages, and limitations of diagnostic tools for EPIApply evidence-based protocols for performing and interpreting ePFTEndoscopic Pancreatic Function Testing (ePFT) in Children: A Position Paper From the NASPGHAN Pancreas CommitteeSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

For this Med Student Over Easy episode, Patricia is joined by Tanner and guest Mary McLean to discuss the topic of Medical Holds and what medical students need to know about taking care of the in the ED. Don't forget, our mother show EM Over Easy is the official podcast of the American College of Osteopathic Emergency Physicians. Visit acoep.org today to learn about an upcoming CME event.

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Imlunestrant with or without abemaciclib in advanced breast cancer: Results of the Phase III EMBER-3 trial (0:00) Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract  Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the Phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1 and PTEN in HR-positive, HER2-negative metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (7:00) Bhave MA et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat 2024;207(3):599-609. Abstract Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), versus fulvestrant for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomized, Phase II trial (10:25) Oliveira M et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25(11):1424-39. Abstract Latest on SERDs: An education session at San Antonio Breast Cancer Symposium 2024 (13:57) Jeselsohn RM. Latest on selective estrogen receptor degraders (SERDs). San Antonio Breast Cancer Symposium 2024;Education Session 5. CME information and select publications

Dr Rinath M Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.

Featuring perspectives from Dr Ramaswamy Govindan and Dr Stephen V Liu, including the following topics: Introduction (0:00) Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Mutation — Dr Govindan (4:04) First- and Later-Line Therapy for Metastatic NSCLC without a Targetable Mutation — Dr Liu (26:59) CME information and select publications

Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches.  CME information and select publications here.

Featuring perspectives from Dr Christopher Lieu and Dr Kanwal Raghav, including the following topics: Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Dr Lieu (0:00) Recent Advances in the Management of Metastatic CRC — Dr Raghav (32:58) CME information and select publications

Clinical investigators discuss available data guiding the management of colorectal cancer.  CME information and select publications here.

Clinical investigators discuss available data guiding the management of colorectal cancer.  CME information and select publications here.

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Follicular Lymphoma (FL) (0:00) Case: A man in his late 60s with relapsed FL who received axicabtagene ciloleucel (axi-cel) but experienced cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and chronic cytopenia (3:50) Published Clinical Data Involving Axi-cel (10:24) Case: A man in his mid 60s with multiple comorbidities and progressive FL who received tisagenlecleucel (tis-cel) (15:34) Published Clinical Data Involving Tis-cel (19:47) Case: A woman in her late 40s with multiple comorbidities and refractory FL who received lisocabtagene maraleucel (liso-cel) after prior mosunetuzumab (22:43) Published Clinical Data Involving Liso-cel (26:05) Incidence and Management of Toxicities Associated with CAR T-Cell Therapy (27:48) Sequencing Considerations and Ongoing Trials Involving CAR T-Cell Therapy (30:35) Practical Considerations and Referrals for CAR T-Cell Therapy Administration (31:59) CME information and select publications

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.

Dr. Julie M. Smith is a trailblazer in large-scale organizational behavior change. Her methods have garnered global awards and are backed by a wealth of case studies featuring organizations of all types and sizes.She has helped organizations identify and execute a wide variety of Vital Behaviors, from key behaviors related to executive decision making for a global oil company to front-line behaviors of flight attendants for a global airline. She's seen it all while helping her clients produce unrivaled results.As CEO of Performance Ally, her mission is to share her life's learning about the most efficient path for leaders at all levels to transform best practices into common practice so they can reliably deliver promised results and create a top workplace culture.Dr. Lori Ludwig is renowned for her extraordinary skill in guiding organizations to align strategy with processes, roles, and behaviors, resulting in high-impact, meaningful results.With 20+ years of consulting experience across diverse sectors, ranging from Fortune 500s to nonprofits and small businesses, Lori's work has had a transformative impact on a global scale. Her projects have elevated productivity and delivered tremendous value for her clients.Serving as Chief Performance Architect at Performance Ally, her mission is to disseminate the science of Organizational Behavior Management (OBM) to create large-scale positive change. Lori simplifies its application, empowering organizations to unleash human potential, amplify impact, and navigate complexity effectively.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

Drs. Chris Conrady and Akbar Shakoor join host Dr. Ben Young to teach us about why intraocular inflammation (IOI) sometimes occurs after intravitreal injections, how to differentiate these cases from endophthalmitis, and how to manage this potentially blinding condition. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Featuring perspectives from Dr Emmanuel S Antonarakis and Prof Karim Fizazi, including the following topics: Introduction: Quality of Life (0:00) PARP Inhibition (PARPi) (7:15) M0 Disease (23:18) Metastatic Hormone-Sensitive Prostate Cancer (34:33) Radiopharmaceuticals (46:16) Other Novel Investigational Approaches for Metastatic Castration-Resistant Prostate Cancer (54:53) CME information and select publications

Dr Emmanuel S Antonarakis from the University of Minnesota in Minneapolis and Professor Karim Fizazi from the Institut Gustave Roussy in Villejuif, France, provide their perspectives on relevant new clinical data in prostate cancer and discuss their application to the care of patients. CME information and select publications here.

How do we create continuing education that prepares clinicians to deliver life-changing diagnoses with both precision and compassion?In this episode, we explore what happens when the scientist's role as a communicator intersects with the lived experience of parenting a child with a rare disease. I'm talking with Dr. Jennifer Brown, a geneticist who recently published a memoir, When the Baby is not OK: Hopes and Genes, based on her experience of parenting children diagnosed with PKU through newborn screening. For CME professionals, this episode is a call to rethink how we center narrative, ethics, and emotional intelligence in our content, especially when evidence alone isn't enough to support meaningful patient care. Learn how outdated narratives and clinical language can alienate patients—and how reframing them can build trust and support retention in care. Hear why integrating lived experience into CME is essential for designing education that resonates beyond the exam room. Discover how personal storytelling, ethical reflection, and patient advocacy can enrich data-driven CME writing. ▶️ Press play to discover how Dr. Jennifer Brown's dual lens—as a geneticist and parent—can sharpen your skills as a more empathetic, informed CME professional. Connect with Jennifer LinkedIn Goodreads  Author Site Bluesky YouTube

Dysfunction of the supranuclear ocular motor pathways typically causes highly localizable deficits. With sophisticated neuroimaging, it is critical to better understand structure-function relationships and precisely localize pathology within the brain. In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Gregory P. Van Stavern, MD, author of the article “Supranuclear Disorders of Eye Movements” in the Continuum® April 2025 Neuro-ophthalmology issue. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Van Stavern is the Robert C. Drews professor of ophthalmology and visual sciences at Washington University in St Louis, Missouri. Additional Resources Read the article: Internuclear and Supranuclear Disorders of Eye Movements Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today I'm interviewing Dr Gregory Van Stavern, who recently authored an article on intranuclear and supranuclear disorders of eye movements for our latest Continuum issue on neuro-ophthalmology. Dr Van Stavern is the Robert C Drews professor of ophthalmology and visual sciences at Washington University in Saint Louis. Dr Van Stavern, welcome, and thank you for joining us today. Why don't you introduce yourself to our audience? Dr Van Stavern: Hi, my name is Gregory Van Stavern. I'm a neuro-ophthalmologist located in Saint Louis, and I'm pleased to be on this show today. Dr Jones: We appreciate you being here, and obviously, any discussion of the visual system is worthwhile. The visual system is important. It's how most of us and most of our patients navigate the world. Roughly 40% of the brain---you can correct me if I'm wrong---is in some way assigned to our visual system. But it's not just about the sensory experience, right? The afferent visual processing. We also have motor systems of control that align our vision and allow us to accurately direct our vision to visual targets of interest. The circuitry is complex, which I think is intimidating to many of us. It's much easier to see a diagram of that than to describe it on a podcast. But I think this is a good opportunity for us to talk about the ocular motor exam and how it helps us localize lesions and, and better understand diagnoses for certain disorders. So, let's get right to it, Dr Van Stavern. If you had from your article, which is outstanding, a single most important message for our listeners about recognizing or treating patients with ocular motor disorders, what would that message be? Dr Van Stavern: Well, I think if we can basically zoom out a little to the big picture, I think it really emphasizes the continuing importance of the examination. History as well, but the examination. I was reading an article the other day that was essentially downplaying the importance of the physical examination in the modern era with modern imaging techniques and technology. But for neurology, and especially neuro-ophthalmology, the history and the examination should still drive clinical decision-making. And doing a careful assessment of the ocular motor system should be able to tell you exactly where the lesion is located, because it's very easy to order a brain MRI, but the MRI is, like Forrest Gump might say, it's like a box of chocolates. You never know what you're going to find. You may find a lot of things, but because you've done the history and the examination, you can see if whatever lesion is uncovered by the MRI is the lesion that explains what's going on with the patient. So even today, even with the most modern imaging techniques we have, it is still really important to know what you're looking for. And that's where the oculomotor examination can be very helpful. Dr Jones: I did not have Forrest Gump on my bingo card today, Dr Van Stavern, but that's a really good analogy, right? If you order the MRI, you don't know what you're going to get. And then- and if you don't have a really well-formed question, then sometimes you get misleading information, right?  Dr Van Stavern: Exactly. Dr Jones: We'll get into some technology here in a minute, because I think that's relevant for this discussion. I think most of our listeners are going to agree with us that the exam is important in neuro-ophthalmology, and neurology broadly. So, I think you have some sympathetic listeners there. Again, the point of the exam is to localize and then lead to a diagnosis that we can help patients with. When you think about neurologic disorders where the ocular motor exam helps you get to the right diagnosis, obviously disorders of eye movements, but sometimes it's a clue to a broader neurologic syndrome. And you have some nice discussions in your article about the ocular motor clues to Parkinson disease or to progressive supranuclear palsy. Tell us a little more about that. In your practice, which neurologic disorders do you find the ocular motor exam being most helpful? Dr Van Stavern: Well, just a very brief digression. So, I started off being an ophthalmology resident, and I do two years of ophthalmology and then switch to neurology. And during neurology residency, I was debating which subspecialty to go into, and I realized that neuro-ophthalmology touches every other subspecialty in neurology. And it goes back to the fact that the visual system is so pervasive and widely distributed throughout the brain. So, if you have a neurologic disease, there is a very good chance it is going to affect vision, maybe in a minor way or a major way. That's why careful assessment of the visual system, and particularly the oculomotor system, is really helpful for many neurologic diseases. Neuromuscular disease, obviously, myasthenia gravis and certain myopathies affect the eye movements. Neurodegenerative diseases, in particular Parkinson's disease and parkinsonian conditions, often affect the eye movements. And in particular, when you're trying to differentiate, is this classic Parkinson's disease? Or is this progressive supranuclear palsy? Is it some broad spectrum multisystem atrophy? The differences between the eye movement disorders, even allowing for the fact that there's overlap, can really help point in one direction to the other, and again, prevent unnecessary testing, unnecessary treatment, and so on. Dr Jones: Very good. And I think, to follow on a thread from that concept with patients who have movement disorders, in my practice, seeing older patients who have a little bit of restriction of vertical gaze is not that uncommon. And it's more common in patients who have idiopathic Parkinson disease. And then we use that part of the exam to help us screen patients for other neurodegenerative syndromes like progressive nuclear- supranuclear palsy. So, do you have any tips for our listeners to- how to look at, maybe, vertical gaze and say, this is maybe a normal age-related degree of change. This is something that might suggest idiopathic Parkinson disease. Or maybe something a little more progressive and sinister like progressive super nuclear palsy? Dr Van Stavern: Well, I think part of the issue- and it's harder to do this without the visual aspect. One of my colleagues always likes to say for a neurologist, the eye movement exam begins and ends with the neurology benediction, just doing the sign of the cross and checking the eye movements. And that's a good place to start. But I think it's important to remember that all you're looking at is smooth pursuit and range of eye movements, and there's much more to the oculomotor examination than that. There's other aspects of eye movement. Looking at saccades can be really helpful; in particular, classically, saccadic movements are selectively abnormal in PSP versus Parkinson's with progressive supranuclear palsy. Saccades, which are essentially rapid movements of the eyes---up and down, in this case---are going to be affected in downward gaze. So, the patient is going to have more difficulty initiating downward saccades, slower saccades, and less range of movement of saccades in downgaze. Whereas in Parkinson's, it's classically upward eye movements and upgaze. So, I think that's something you won't be able to see if you're just doing, looking at, you know, your classic, look at your eye movements, which are just assessing, smooth pursuit. Looking carefully at the eye movements during fixation can be helpful. Another aspect of many parkinsonian conditions is saccadic intrusions, where there's quick movements or saccades of the eye that are interrupting fixation. Much, much more common in PSP than in Parkinson's disease. The saccadic intrusions are what we call square-wave jerks because of what they look like. Eye movement recordings are much larger amplitude in PSP and other multisystem atrophy diseases than with Parkinson's. And none of these are perfect differentiators, but the constellation of those findings, a patient with slow downwards saccades, very large amplitude, and frequent saccadic intrusions might point you more towards this being PSP rather than Parkinson's. Dr Jones: That's a great pearl, thinking about the saccades in addition to the smooth pursuit. So, thank you for that. And you mentioned eye movement measurements. I think it's simultaneously impressive and a little scary that my phone can tell when I'm looking at it within a few degrees of visual attention. So, I imagine there are automated tools to analyze eye movement. Tell us, what's the state of the art there, and what should our listeners be aware of in terms of tools that are available and what they can and can't do? Dr Van Stavern: Well, I could tell you, I mean, I see neuro-ophthalmic patients with eye movement disorders every day and we do not have any automated tools for eye movement. We have a ton of imaging techniques for imaging the optic nerve and the retina in different ways, but we don't routinely employ eye movement recording devices. The only time we usually do that is in somebody where we suspect they have a central or peripheral vestibular disease and we send them for vestibular testing, for eye movement recordings. There is interest in using- I know, again, sort of another digression, but if you're looking at the HINTS technique, which is described in the chapter to differentiate central from peripheral disease, which is a very easy, useful way to differentiate central from peripheral or peripheral vestibular disease. And again, in the acute setting, is this a stroke or not a stroke? Is it the brain or is it the inner ear? Part of the problem is that if you're deploying this widespread, the people who are doing it may not be sufficiently good enough at doing the test to differentiate, is a positive or negative test? And that's where some people have started introducing this into the emergency room, these eye movement recording devices, to give the- using, potentially, AI and algorithms to help the emergency room physicians say, all right, this looks like a stroke, we need to admit the patient, get an MRI and so on, versus, this is vestibular neuritis or an inner ear problem, treat them symptomatically, follow up as an outpatient. That has not yet been widely employed. It's a similar way that a lot of institutions are having fundus photography and OCT devices placed in the emergency room to aid the emergency room physician for patients who present with acute vision issues. So, I think that could be the future. It probably would be something that would be AI-assisted or AI-driven. But I can tell you at least at our institution and most of the ones I know of, it is not routinely employed yet. Dr Jones: So maybe on the horizon, AI kind of facilitated tools for eye movement disorder interpretation, but it's not ready for prime time yet. Is that a fair summary? Dr Van Stavern: In my opinion, yes. Dr Jones: Good to know. This has struck me every time I've read about ocular motor anatomy and ocular motor disorders, whether they're supranuclear or intranuclear disorders. The anatomy is complex, the circuitry is very complicated. Which means I learn it and then I forget it and then I relearn it. But some of the anatomy isn't even fully understood yet. This is a very complex real estate in the brainstem. Why do you think the neurophysiology and neuroanatomy is not fully clarified yet? And is there anything on the horizon that might clarify some of this anatomy? Dr Van Stavern: The very first time I encountered this topic as an ophthalmology resident and later as a neurology resident, I just couldn't understand how anyone could really understand all of the circuitry involved. And there is a lot of circuitry that is involved in us simply having clear, single binocular vision with the afferent and efferent system working in concert. Even in arch. In my chapter, when you look at the anatomy and physiology of the smooth pursuit system or the vertical gaze pathways, there's a lot of, I'll admit it, there's a lot of hand waving and we don't completely understand it. I think a lot of it has to do with, in the old days, a lot of the anatomy was based on lesions, you know, lesion this area either experimentally or clinically. And that's how you would determine, this is what this region of the brain is responsible for. Although we've gotten more sophisticated with better imaging, with functional connectivity MRI and so on, all of those have limitations. And that's why I still don't think we completely understand all the way this information is integrated and synthesized, and, to get even more big level and esoteric, how this makes its way into our conscious mind. And that has to do with self-awareness and consciousness, which is a whole other kettle of fish. It's just really complicated. I think when I'm at least talking to other neurologists and residents, I try to keep it as simple as possible from a clinical standpoint. If you see someone with an eye movement problem, try to see if you can localize it to which level you're dealing with. Is it a muscle problem? Is it neuromuscular junction? Is it nerve? Is it nucleus? Is it supranuclear? If you can put it at even one of those two levels, you have eliminated huge territories of neurologic real estate, and that will definitely help you target and tailor your workup. So, again, you're not costing the patient in the healthcare system hundreds of thousands of dollars. Dr Jones: Great points in there. And I think, you know, if we can't get it down to the rostral interstitial nucleus of the medial longitudinal fasciculus, if we can get it to the brainstem, I think that's obviously- that's helpful in its own right. And I imagine, Dr Van Stavern, managing patients with persistent ocular motor disorders is a challenge. We take foveation for granted, right, when we can create these single cortical images. And I imagine it's important for daily function and difficult for patients who lose that ability to maintain their ocular alignment. What are some of the clinical tools that you use in your practice that our listeners should be aware of to help patients that have a persistent supranuclear disorder of ocular movement? Dr Van Stavern: Well, I think you tailor your treatment to the symptoms, and if it's directly due to underlying condition, obviously you treat the underlying condition. If they have sixth nerve palsy because of a skull base tumor, obviously you treat the skull base tumor. But from a practical standpoint, I think it depends on what the symptom is, what's causing it, and how much it's affecting their quality of life. And everyone is really different. Some patients have higher levels of tolerance for blurred vision and double vision. For things- for patients who have double vision, depending upon the underlying cause we can sometimes use prisms and glasses. Prisms are simply- a lot of people just think prism is this, like, mystical word that means a lot. It's simply just an optical device that bends light. So, it essentially bends light to allow the eyes- basically, the image to fall on the fovea in both eyes. And whether the prisms help or not is partly dependent upon how large the misalignment is. If somebody has a large degree of misalignment, you're not going to fix that with prism. The amount of prism you'd need to bend the light enough to land on the fovea in both eyes would cause so much blur and distortion that it would essentially be a glorified patch. So, for small ranges of misalignment, prisms are often very helpful, that we can paste over glasses or grind into glasses. For larger degrees of misalignment that- let's say it is due to some skull base tumor or brain stem lesion that is not going to get better, then eye muscle surgery is a very effective option. We usually like to give people a long enough period of time to make sure there's no change before proceeding with eye muscle surgery. Dr Jones: Very helpful. So, prisms will help to a limited extent with misalignment, and then surgery is always an option if it's persistent. That's a good pearl for, I think, our listeners to take away. Dr Van Stavern: And even in those circumstances, even prisms and eye muscle surgery, the goal is primarily to cause single binocular vision and primary gaze at near. Even in those cases, even with the best results, patients are still going to have double vision, eccentric gaze. For most people, that's not a big issue, but we have had a few patients… I had a couple of patients who were truck drivers who were really bothered by the fact that when they look to the left, let's say because it's a 4th nerve palsy on the right, they have double vision. I had a patient who was a golfer who was really, really unhappy with that. Most people are okay with that, but it all depends upon the individual patient and what they use their vision for. Dr Jones: That's a great point. There's not enough neurologists in the world. I know for a fact there are not enough neuro-ophthalmologists in the world, right? There's just not many people that have that dual expertise. You mentioned that you started with ophthalmology and then did neurology training. What do you think the pipeline looks like for neuro-ophthalmology? Do you see growing interest in this among trainees, or unchanged? What are your thoughts about that? Dr Van Stavern: No, that's a continuing discussion we're having within our own field about how to attract more residents into neuro-ophthalmology. And there's been a huge shift. In the past, this was primarily ophthalmology-driven. Most neuro-ophthalmologists were trained in ophthalmology initially before doing a fellowship. The last twenty years, it switched. Now there's an almost 50/50 division between neurologists and ophthalmologists, as more neurologists have become more interested. This is probably a topic more for the ophthalmology equivalent of Continuum. One of the perceptions is this is not a surgical subspecialty, so a lot of ophthalmology residents are disincentivized to pursue it. So, we have tried to change that. You can do neuro-ophthalmology and do eye muscle surgery or general ophthalmology. I think it really depends upon whether you have exposure to a neuro-ophthalmologist during your neurology residency. If you do not have any exposure to neuro-ophthalmology, this field will always seem mysterious, a huge black box, something intimidating, and something that is not appealing to a neurologist. I and most of my colleagues make sure to include neurology residents in our clinic so they at least have exposure to it. Dr Jones: That's a great point. If you never see it, it's hard to envision yourself in that practice. So, a little bit of a self-fulfilling prophecy. If you don't have neuro-ophthalmologists, it's hard to expose that practice to trainees. Dr Van Stavern: And we're also trying; I mean, we make sure to include medical students, bring them to our meetings, present research to try to get them interested in this field at a very early stage. Dr Jones: Dr Van Stavern, great discussion, very helpful. I want to thank you for joining us today. I want to thank you for not just a great podcast, but also just a wonderful article on ocular motor disorders, supranuclear and intranuclear. I learned a lot, and hopefully our listeners did too. Dr Van Stavern: Well, thanks. I really appreciate doing this. And I love Continuum. I learn something new every time I get another issue. Dr Jones: Well, thanks for reading it. And I'll tell you as the editor of Continuum, I learn a lot reading these articles. So, it's really a joy to get to read, up to the minute, cutting-edge clinical content for neurology. Again, we've been speaking with Dr Gregory Van Stavern, author of a fantastic article on intranuclear and supranuclear disorders of eye movements in Continuum's most recent issue on neuro-ophthalmology. Please check it out, and thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Pediatrician Dr. Jill Schaffeld consults Dr. Bob DeFoor from the Cincinnati Children's Division of Urology on prenatal hydronephrosis.  Episode recorded on April 3, 2025. Resources discussed in this episode: - Prenatal Hydronephrosis CPST CME & MOC Part 2 We are proud to offer CME and MOC Part 2 from Cincinnati Children's.  Credit is free and registration is required.  Please click here to claim CME credit via the post-test under "Launch Activity." Financial Disclosure:  The following relevant financial relationships have been disclosed: None All relevant financial relationships listed have been mitigated. Remaining persons in control of content have no relevant financial relationships. Accreditation In support of improving patient care, Cincinnati Children's Hospital Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Specific accreditation information will be provided for each activity. Physicians: Cincinnati Children's designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses: This activity is approved for a maximum 0.5 continuing nursing education (CNE) contact hours. MOCpt2: Completion of this CME activity, which includes learner assessment and feedback, enables the learner to earn up to 0.5 points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. Cincinnati Children's submits MOC/CC credit for board diplomates. Credits AMA PRA Category 1 Credits™ (0.50 hours), ABP MOC Part 2 (0.50 hours), CME - Non-Physician (Attendance) (0.50 hours), Nursing CE (0.50 hours)  

The CME's 13th birthday is coming up, and you know what that means: It's pledge month! Now through June 1, GET 50% OFF A NEW MONTHLY OR ANNUAL PATREON SUBSCRIPTION when you use the code CME13 at checkout! Get on it! Join the team! Support the community! Stick it to the man! Did Jack Della Maddalena ruin everything? Well, it's a fluid situation. As we recorded this episode of the Proper, the MMA world awaited an announcement from Dana White we all assume(d) will be the main event of UFC 317 coming up in June for International Fight Week. What will we get? Ilia Topuria vs. Islam Makhachev? Or Topuria vs. Charles Oliveira? By the time you listen to this, you might well know the answer. It's possible that Della Maddalena's welterweight title win over Belal Muhammad at last weekend's UFC 315 will tip a succession of dominoes that could result in Makhachev moving up to 170 pounds to fight JDM, which would leave Topuria to fight Oliveira. And let's be honest, that would kinda suck. It was a brilliant performance by Flatnose Jackie to take the title on Saturday. But at what cost? Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Dianah T. Lake, MD (also known as Dr. Di) is an emergency medicine physician, best-selling author, speaker, fitness & weight loss coach, menopause wellness expert, autism parent advocate and founder of Dr. Di Fitness. Using her clinical experience as an emergency medicine physician, and her knowledge and expertise as a fitness and weight loss coach, Dr. Di promotes a holistic approach to disease prevention, healthy living, fitness, weight loss, menopause wellness, longevity and overall wellness.  She is sought after to speak on various health and wellness topics for churches, conventions, conferences, summits, podcasts, magazines and TV shows. Work with Dr. Di to sculpt a fit healthy body that you absolutely love, create a happy, healthy and holistic lifestyle, customize a nutrition plan you can utilize for a lifetime, work with a partner in a holistic approach to disease prevention, fitness, menopause relief, weight loss, longevity and overall wellness, develop the fitness mindset so you can feel sexy, strong, confident and youthful again, and lose weight effectively with or without weight loss medications. Dr. Di enjoys gardening, running, tennis, bodybuilding, dancing, spa days and trips to exotic locations around the world. She is a leader and sound voice in the health and fitness space.  She helps her clients go from feeling drained, exhausted, overwhelmed and overweight to fit, fierce, fiery and fabulous! Some of the topics we discussed were: How Dr. Di's fitness journey developed into her fitness and weight loss coaching programHow Dr. Di emphasized personal development in her fitness journey What Dr. Di teaches in her program that should be learned in medical school How Dr. Di's program provides members with the opportunity to use CME money to get fit on group retreats How clinicians in Dr. Di's coaching program apply the information they learn to what they're doing in their clinical practice How Dr. Di gives CME credits to more than solely physicians How Dr. Di got into running and her love for running started And more!Learn more about me or schedule a FREE coaching call:https://www.joyfulsuccessliving.com/ Join the Voices of Women Physicians Facebook Group:https://www.facebook.com/groups/190596326343825/Connect with Dr. Lake: Instagram:@DrDiFitLife Facebook:@DrDiFitness LinkedIn:@DrDianahLake Youtube:@Dr.DianahLake2991 Schedule A Free Fitness Breakthrough Session with Dr. Dianah here:https://DrDiFitLife.as.me/?appointmentType=5524801 Learn more about her menopause wellness program here:Dr. Dianah - Get Menopause Relief Now Join Dr. Di in her free fitness accountability Facebook community for successful female professionals, Professional Women Getting Fit:https://m.facebook.com/groups/143455166379490 

So even the people that follow the topic closely are stunned by the digital landscape that engulfs our children, how quickly it evolves, and the potential social cost. Two people in a unique position to explain all this are our guest today, Jeffrey Chester and Kathryn Montgomery, both from the Center for Digital Democracy. Jeff is executive director of the Center, and Kathryn is its research director and senior strategist, as well as professor emerita of communication at American University. Jeff and Kathryn have been pioneers in this work and have been uniquely strong voices for protecting children. Interview Summary Let me congratulate the two of you for being way ahead of your time. I mean the two of you through your research and your advocacy and your organizational work, you were onto these things way before most people were. I'm really happy that you're joining us today, and welcome to our podcast. Kathryn, let me begin with you. So why be concerned about this digital landscape? Kathryn - Well, certainly if we're talking about children and youth, we have to pay attention to the world they live in. And it's a digital world as I think any parent knows, and everybody knows. In fact, for all of us, we're living in a digital world. So young people are living their lives online. They're using mobile phones and mobile devices all the time. They're doing online video streaming. They form their communications with their peers online. Their entire lives are completely integrated into this digital media landscape, and we must understand it. Certainly, the food and beverage industry understand it very well. And they have figured out enormously powerful ways to reach and engage young people through these digital media. You know, the extent of the kids' connection to this is really remarkable. I just finished a few minutes ago recording a podcast with two people involved with the Children and Screens organization. And, Chris Perry, who's the executive director of that organization and Dmitri Christakis who was with us as well, were saying that kids sometimes check their digital media 300 times a day. I mean, just unbelievable how much of this there is. There's a lot of reasons to be concerned. Let's turn our attention to how bad it is, what companies are doing, and what might be done about it. So, Jeff, tell us if you would, about the work of the Center for Digital Democracy. Jeff - Well, for more than a quarter of a century, we have tracked the digital marketplace. As you said at the top, we understood in the early 1990s that the internet, broadband what's become today's digital environment, was going to be the dominant communications system. And it required public interest rules and policies and safeguards. So as a result, one of the things that our Center does is we look at the entire digital landscape as best as we can, especially what the ultra-processed food companies are doing, but including Google and Meta and Amazon and GenAI companies. We are tracking what they're doing, how they're creating the advertising, what their data strategies are, what their political activities are in the United States and in many other places in the world. Because the only way we're going to hold them accountable is if we know what they're doing and what they intend to do. And just to quickly follow up, Kelly, the marketers call today's global generation of young people Generation Alpha. Meaning that they are the first generation to be born into this complete digital landscape environment that we have created. And they have developed a host of strategies to target children at the earliest ages to take advantage of the fact that they're growing up digitally. Boy, pretty amazing - Generation Alpha. Kathryn, I have kind of a niche question I'd like to ask you because it pertains to my own career as well. So, you spent many years as an academic studying and writing about these issues, but also you were a strong advocacy voice. How did you go about balancing the research and the objectivity of an academic with advocacy you were doing? Kathryn - I think it really is rooted in my fundamental set of values about what it means to be an academic. And I feel very strongly and believe very strongly that all of us have a moral and ethical responsibility to the public. That the work we do should really, as I always have told my students, try to make the world a better place. It may seem idealistic, but I think it is what our responsibility is. And I've certainly been influenced in my own education by public scholars over the years who have played that very, very important role. It couldn't be more important today than it has been over the years. And I think particularly if you're talking about public health, I don't think you can be neutral. You can have systematic ways of assessing the impact of food marketing, in this case on young people. But I don't think you can be totally objective and neutral about the need to improve the public health of our citizens. And particularly the public health of our young people. I agree totally with that. Jeff let's talk about the concept of targeted marketing. We hear that term a lot. And in the context of food, people talk about marketing aimed at children as one form of targeting. Or, toward children of color or people of color in general. But that's in a way technological child's play. I understand from you that there's much more precise targeting than a big demographic group like that. Tell us more. Jeff - Well, I mean certainly the ultra-processed food companies are on the cutting edge of using all the latest tools to target individuals in highly personalized way. And I think if I have one message to share with your listeners and viewers is that if we don't act soon, we're going to make an already vulnerable group even more exposed to this kind of direct targeted and personalized marketing. Because what artificial intelligence allows the food and beverage companies and their advertising agencies and platform partners to do is to really understand who we are, what we do, where we are, how we react, behave, think, and then target us accordingly using all those elements in a system that can create this kind of advertising and marketing in minutes, if not eventually milliseconds. So, all of marketing, in essence, will be targeted because they know so much about us. You have an endless chain of relationships between companies like Meta, companies like Kellogg's, the advertising agencies, the data brokers, the marketing clouds, et cetera. Young people especially, and communities of color and other vulnerable groups, have never been more exposed to this kind of invasive, pervasive advertising. Tell us how targeted it can be. I mean, let's take a 11-year-old girl who lives in Wichita and a 13-year-old boy who lives in Denver. How much do the companies know about those two people as individuals? And how does a targeting get market to them? Not because they belong to a big demographic group, but because of them as individuals. Jeff - Well, they certainly are identified in various ways. The marketers know that there are young people in the household. They know that there are young people, parts of families who have various media behaviors. They're watching these kinds of television shows, especially through streaming or listening to music or on social media. Those profiles are put together. And even when the companies say they don't exactly know who the child is or not collecting information from someone under 13 because of the privacy law that we helped get enacted, they know where they are and how to reach them. So, what you've had is an unlimited amassing of data power developed by the food and beverage companies in the United States over the last 25 years. Because really very little has been put in their way to stop them from what they do and plan to do. So presumably you could get some act of Congress put in to forbid the companies from targeting African American children or something like that. But it doesn't sound like that would matter because they're so much more precise in the market. Yes. I mean, in the first place you couldn't get congress to pass that. And I think this is the other thing to think about when you think about the food and beverage companies deploying Generative AI and the latest tools. They've already established vast, what they call insights divisions, market research divisions, to understand our behavior. But now they're able to put all that on a fast, fast, forward basis because of data processing, because of data clouds, let's say, provided by Amazon, and other kinds of tools. They're able to really generate how to sell to us individually, what new products will appeal to us individually and even create the packaging and the promotion to be personalized. So, what you're talking about is the need for a whole set of policy safeguards. But I certainly think that people concerned about public health need to think about regulating the role of Generative AI, especially when it comes to young people to ensure that they're not marketed to in the ways that it fact is and will continue to do. Kathryn, what about the argument that it's a parent's responsibility to protect their children and that government doesn't need to be involved in this space? Kathryn - Well, as a parent, I have to say is extremely challenging. We all do our best to try to protect our children from unhealthy influences, whether it's food or something that affects their mental health. That's a parent's obligation. That's what a parent spends a lot of time thinking about and trying to do. But this is an environment that is overwhelming. It is intrusive. It reaches into young people's lives in ways that make it virtually impossible for parents to intervene. These are powerful companies, and I'm including the tech companies. I'm including the retailers. I'm including the ad agencies as well as these global food and beverage companies. They're extremely powerful. As Jeff has been saying, they have engaged and continue to engage in enormous amounts of technological innovation and research to figure out precisely how to reach and engage our children. And it's too much for parents. And I've been saying this for years. I've been telling legislators this. I've been telling the companies this. It's not fair. It's a very unfair situation for parents. That makes perfect sense. Well, Jeff, your Center produces some very helpful and impressive reports. And an example of that is work you've done on the vast surveillance of television viewers. Tell us more about that, if you would. Jeff - Well, you know, you have to keep up with this, Kelly. The advocates in the United States and the academics with some exceptions have largely failed to address the contemporary business practices of the food and beverage companies. This is not a secret what's going on now. I mean the Generative AI stuff and the advanced data use, you know, is recent. But it is a continuum. And the fact is that we've been one of the few groups following it because we care about our society, our democracy, our media system, et cetera. But so much more could be done here to track what the companies are doing to identify the problematic practices, to think about counter strategies to try to bring change. So yes, we did this report on video streaming because in fact, it's the way television has now changed. It's now part of the commercial surveillance advertising and marketing complex food and beverage companies are using the interactivity and the data collection of streaming television. And we're sounding the alarm as we've been sounding now for too long. But hopefully your listeners will, in fact, start looking more closely at this digital environment because if we don't intervene in the next few years, it'll be impossible to go back and protect young people. So, when people watch television, they don't generally realize or appreciate the fact that information is being collected on them. Jeff - The television watches you now. The television is watching you now. The streaming companies are watching you now. The device that brings you streaming television is watching you now is collecting all kinds of data. The streaming device can deliver personalized ads to you. They'll be soon selling you products in real time. And they're sharing that data with companies like Meta Facebook, your local retailers like Albertsons, Kroger, et cetera. It's one big, huge digital data marketing machine that has been created. And the industry has been successful in blocking legislation except for the one law we were able to get through in 1998. And now under the Trump administration, they have free reign to do whatever they want. It's going to be an uphill battle. But I do think the companies are in a precarious position politically if we could get more people focused on what they're doing. Alright, we'll come back to that. My guess is that very few people realize the kind of thing that you just talked about. That so much information is being collected on them while they're watching television. The fact that you and your center are out there making people more aware, I think, is likely to be very helpful. Jeff - Well, I appreciate that, Kelly, but I have to say, and I don't want to denigrate our work, but you know, I just follow the trades. There's so much evidence if you care about the media and if you care about advertising and marketing or if you care, just let's say about Coca-Cola or Pepsi or Mondalez. Pick one you can't miss all this stuff. It's all there every day. And the problem is that there has not been the focus, I blame the funders in part. There's not been the focus on this marketplace in its contemporary dimensions. I'd like to ask you both about the legislative landscape and whether there are laws protecting people, especially children from this marketing. And Kathy, both you and Jeff were heavily involved in advocacy for a landmark piece of legislation that Jeff referred to from 1998, the Children's Online Privacy Protection Act. What did this act involve? And now that we're some years in, how has it worked? Kathryn - Well, I always say I've been studying advertising in the digital media before people even knew there was going to be advertising in digital media. Because we're really talking about the earliest days of the internet when it was being commercialized. But there was a public perception promoted by the government and the industry and a lot of other institutions and individuals that this was going to be a whole new democratic system of technology. And that basically it would solve all of our problems in terms of access to information. In terms of education. It would open up worlds to young people. In many ways it has, but they didn't talk really that much about advertising. Jeff and I working together at the Center for Media Education, were already tracking what was going on in that marketplace in the mid-1990s when it was very, very new. At which point children were already a prime target. They were digital kids. They were considered highly lucrative. Cyber Tots was one of the words that was used by the industry. What we believed was that we needed to get some public debate and some legislation in place, some kinds of rules, to guide the development of this new commercialized media system. And so, we launched a campaign that ultimately resulted in the passage of the Children's Online Privacy Protection Act. Now it only governs commercial media, online, digital media that targets children under the age of 13, which was the most vulnerable demographic group of young people. We believe protections are really, really very important for teenagers. There's a lot of evidence for that now, much more research actually, that's showing their vulnerable abilities. And it has required companies to take young people into account when developing their operations. It's had an impact internationally in a lot of other countries. It is just the barest minimum of what we need in terms of protections for young people. And we've worked with the Federal Trade Commission over the years to ensure that those rules were updated and strengthened so that they would apply to this evolving digital media system. But now, I believe, that what we need is a more global advocacy strategy. And we are already doing that with advocates in other countries to develop a strategy to address the practices of this global industry. And there are some areas where we see some promising movement. The UK, for example, passed a law that bans advertising on digital media online. It has not yet taken effect, but now it will after some delays. And there are also other things going on for ultra processed foods, for unhealthy foods and beverages. So, Kathryn has partly answered this already, Jeff, but let me ask you. That act that we've talked about goes back a number of years now, what's being done more recently on the legislative front? Perhaps more important than that, what needs to be done? Well, I have to say, Kelly, that when Joe Biden came in and we had a public interest chair at the Federal Trade Commission, Lena Khan, I urged advocates in the United States who are concerned about unhealthy eating to approach the Federal Trade Commission and begin a campaign to see what we could do. Because this was going to be the most progressive Federal Trade Commission we've had in decades. And groups failed to do so for a variety of reasons. So that window has ended where we might be able to get the Federal Trade Commission to do something. There are people in the United States Congress, most notably Ed Markey, who sponsored our Children's Privacy Law 25 years ago, to get legislation. But I think we have to look outside of the United States, as Kathryn said. Beyond the law in the United Kingdom. In the European Union there are rules governing digital platforms called the Digital Services Act. There's a new European Union-wide policy safeguards on Generative AI. Brazil has something similar. There are design codes like the UK design code for young people. What we need to do is to put together a package of strategies at the federal and perhaps even state level. And there's been some activity at the state level. You know, the industry has been opposed to that and gone to court to fight any rules protecting young people online. But create a kind of a cutting-edge set of practices that then could be implemented here in the United States as part of a campaign. But there are models. And how do the political parties break down on this, these issues? Kathryn - I was going to say they break down. Jeff - The industry is so powerful still. You have bipartisan support for regulating social media when it comes to young people because there have been so many incidences of suicide and stalking and other kinds of emotional and psychological harms to young people. You have a lot of Republicans who have joined with Democrats and Congress wanting to pass legislation. And there's some bipartisan support to expand the privacy rules and even to regulate online advertising for teens in our Congress. But it's been stymied in part because the industry has such an effective lobbying operation. And I have to say that in the United States, the community of advocates and their supporters who would want to see such legislation are marginalized. They're under underfunded. They're not organized. They don't have the research. It's a problem. Now all these things can be addressed, and we should try to address them. But right now it's unlikely anything will pass in the next few months certainly. Kathryn - Can I just add something? Because I think what's important now in this really difficult period is to begin building a broader set of stakeholders in a coalition. And as I said, I think it does need to be global. But I want to talk about also on the research front, there's been a lot of really important research on digital food marketing. On marketing among healthy foods and beverages to young people, in a number of different countries. In the UK, in Australia, and other places around the world. And these scholars have been working together and a lot of them are working with scholars here in the US where we've seen an increase in that kind of research. And then advocates need to work together as well to build a movement. It could be a resurgence that begins outside of our country but comes back in at the appropriate time when we're able to garner the kind of support from our policymakers that we need to make something happen. That makes good sense, especially a global approach when it's hard to get things done here. Jeff, you alluded to the fact that you've done work specifically on ultra processed foods. Tell us what you're up to on that front. Jeff - As part of our industry analysis we have been tracking what all the leading food and beverage companies are doing in terms of what they would call their digital transformation. I mean, Coca-Cola and Pepsi on Mondelez and Hershey and all the leading transnational processed food companies are really now at the end of an intense period of restructuring to take advantage of the capabilities provided by digital data and analytics for the further data collection, machine learning, and Generative AI. And they are much more powerful, much more effective, much more adept. In addition, the industry structure has changed in the last few years also because of digital data that new collaborations have been created between the platforms, let's say like Facebook and YouTube, the food advertisers, their marketing agencies, which are now also data companies, but most notably the retailers and the grocery stores and the supermarkets. They're all working together to share data to collaborate on marketing and advertising strategies. So as part of our work we've kept abreast of all these things and we're tracking them. And now we are sharing them with a group of advocates outside of the United States supported by the Bloomberg Philanthropies to support their efforts. And they've already made tremendous progress in a lot of areas around healthy eating in countries like Mexico and Argentina and Brazil, et cetera. And I'm assuming all these technological advances and the marketing muscle, the companies have is not being used to market broccoli and carrots and Brussels sprouts. Is that right? Jeff - The large companies are aware of changing attitudes and the need for healthy foods. One quick takeaway I have is this. That because the large ultra processed food companies understand that there are political pressures promoting healthier eating in North America and in Europe. They are focused on expanding their unhealthy eating portfolio, in new regions specifically Asia Pacific, Africa, and Latin America. And China is a big market for all this. This is why it has to be a global approach here, Kelly. First place, these are transnational corporations. They are creating the, our marketing strategies at the global level and then transmitting them down to be tailored at the national or regional level. They're coming up with a single set of strategies that will affect every country and every child in those countries. We need to keep track of that and figure out ways to go after that. And there are global tools we might be able to use to try to protect young people. Because if you could protect young, a young person in China, you might also be able to protect them here in North Carolina. This all sounds potentially pretty scary, but is there reason to be optimistic? Let's see if we can end on a positive note. What do you think. Do you have reason to be optimistic? Kathryn - I've always been an optimist. I've always tried to be an optimist, and again, what I would say is if we look at this globally and if we identify partners and allies all around the world who are doing good work, and there are many, many, many of them. And if we work together and continue to develop strategies for holding this powerful industry and these powerful industries accountable. I think we will have success. And I think we should also shine the spotlight on areas where important work has already taken place. Where laws have been enacted. Where companies have been made to change their practices and highlight those and build on those successes from around the world. Thanks. Jeff, what about you? Is there reason to be optimistic? Well, I don't think we can stop trying, although we're at a particularly difficult moment here in our country and worldwide. Because unless we try to intervene the largest corporations, who are working and will work closely with our government and other government, will be able to impact our lives in so many ways through their ability to collect data. And to use that data to target us and to change our behaviors. You can change our health behaviors. You can try to change our political behaviors. What the ultra-processed food companies are now able to do every company is able to do and governments are able to do. We have to expose what they're doing, and we have to challenge what they're doing so we can try to leave our kids a better world. It makes sense. Do you see that the general public is more aware of these issues and is there reason to be optimistic on that front? That awareness might lead to pressure on politicians to change things? Jeff - You know, under the Biden administration, the Federal Trade Commission identified how digital advertising and marketing works and it made it popular among many, many more people than previously. And that's called commercial surveillance advertising. The idea that data is collected about you is used to advertise and market to you. And today there are thousands of people and certainly many more advocacy groups concerned about commercial surveillance advertising than there were prior to 2020. And all over the world, as Kathryn said, in countries like in Brazil and South Africa and Mexico, advocates are calling attention to all these techniques and practices. More and more people are being aware and then, you know, we need obviously leaders like you, Kelly, who can reach out to other scholars and get us together working together in some kind of larger collaborative to ensure that these techniques and capabilities are exposed to the public and we hold them accountable. Bios Kathryn Montgomery, PhD. is Research Director and Senior Strategist for the Center for Digital Democracy (CDD). In the early 90s, she and Jeff Chester co-founded the Center for Media Education (CME), where she served as President until 2003, and which was the predecessor organization to CDD. CME spearheaded the national campaign that led to passage of the 1998 Children's Online Privacy Protection Act (COPPA) the first federal legislation to protect children's privacy on the Internet. From 2003 until 2018, Dr. Montgomery was Professor of Communication at American University in Washington, D.C., where she founded and directed the 3-year interdisciplinary PhD program in Communication. She has served as a consultant to CDD for a number of years and joined the full-time staff in July 2018. Throughout her career, Dr. Montgomery has written and published extensively about the role of media in society, addressing a variety of topics, including: the politics of entertainment television; youth engagement with digital media; and contemporary advertising and marketing practices. Montgomery's research, writing, and testimony have helped frame the national public policy debate on a range of critical media issues. In addition to numerous journal articles, chapters, and reports, she is author of two books: Target: Prime Time – Advocacy Groups and the Struggle over Entertainment Television (Oxford University Press, 1989); and Generation Digital: Politics, Commerce, and Childhood in the Age of the Internet (MIT Press, 2007). Montgomery's current research focuses on the major technology, economic, and policy trends shaping the future of digital media in the Big Data era. She earned her doctorate in Film and Television from the University of California, Los Angeles. Jeff Chester is Executive Director of the Center for Digital Democracy (CDD), a Washington, DC non-profit organization. CDD is one of the leading U.S. NGOs advocating for citizens, consumers and other stakeholders on digital privacy and consumer protections online. Founded in 1991, CDD (then known as the Center for Media Education) led the campaign for the enactment of the Children's Online Privacy Protection Act (COPPA, 1998). During the 1990s it also played a prominent role in such issues as open access/network neutrality, diversity of media ownership, public interest policies for children and television, as well the development of the FCC's “E-Rate” funding to ensure that schools and libraries had the resources to offer Internet services. Since 2003, CDD has been spearheading initiatives designed to ensure that digital media in the broadband era fulfill their democratic potential. A former investigative reporter, filmmaker and Jungian-oriented psychotherapist, Jeff Chester received his M.S.W. in Community Mental Health from U.C. Berkeley. He is the author of Digital Destiny: New Media and the Future of Democracy (The New Press, 2007), as well as articles in both the scholarly and popular press. During the 1980s, Jeff co-directed the campaign that led to the Congressional creation of the Independent Television Service (ITVS) for public TV. He also co-founded the National Campaign for Freedom of Expression, the artist advocacy group that supported federal funding for artists. In 1996, Newsweek magazine named Jeff Chester one of the Internet's fifty most influential people. He was named a Stern Foundation “Public Interest Pioneer” in 2001, and a “Domestic Privacy Champion” by the Electronic Privacy Information Center in 2011. CDD is a member of the Transatlantic Consumer Dialogue (TACD). Until January 2019, Jeff was the U.S. co-chair of TACD's Information Society (Infosoc) group, helping direct the organization's Transatlantic work on data protection, privacy and digital rights.

Cheaper derm meds - with Dr. Jules Lipoff! -Nemolizumab trials for AD -You can use LOTS of antihistamines in CSU -Learn more about Dr. Lipoff at www.juleslipoff.com/ or on social media @juleslipoff !Continue your dermatological education with Dialogues in Dermatology!https://www.aad.org/member/education/professional-education/dialoguesDiscover affordable medication options for your patients at Noblesville Low Cost Pharmacy! https://www.noblesvillelowcostpharmacy.com/Join Luke's CME experience on Jak inhibitors! rushu.gathered.com/invite/ELe31Enb69Register for the U of U Practical Derm course!medicine.utah.edu/dermatology/educ…nities/practicalLearn more about the U of U Dermatology ECHO model!physicians.utah.edu/echo/dermatology-primarycareWant to donate to the cause? Do so here!
Donate to the podcast: uofuhealth.org/dermasphere
Check out our video content on YouTube:
www.youtube.com/@dermaspherepodcast
and VuMedi!: www.vumedi.com/channel/dermasphere/
The University of Utah's Dermatology
ECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -
⁠ Connect with us!
- Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC
- Instagram: dermaspherepodcast
- Facebook: www.facebook.com/DermaspherePodcast/
- Check out Luke and Michelle's other podcast,
SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our
friends at:
- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)
- ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learn
more dermatology!

Listen as the original 3 amigos; Drew, Tanner, and Andy discuss the past 9 years of their careers under the question "what's surprised you?". Don't forget, we are the official podcast of the American College of Osteopathic Emergency Physicians, visit ACOEP.org to learn more about how you can see our show LIVE and in person and get some high quality CME.

Featuring perspectives from Dr Christopher Flower and Dr Krish Patel, including the following topics: Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Non-Hodgkin Lymphoma (NHL) — Dr Patel (0:00) Other Available and Emerging Novel Therapies for NHL — Dr Flowers (22:07) CME information and select publications

Clinical investigators discuss available data guiding the management of non-Hodgkin lymphoma.  CME information and select publications here.

Drs. Safa Rahmani, Jesse Sengillo, and Kat Talcott join for a journal club episode. Faricimab Switch Study (https://www.ophthalmologyretina.org/article/S2468-6530(25)00124-1/abstract) Gender Differences in Communication (https://www.ajo.com/article/S0002-9394(25)00133-3/fulltext) PE Acquisitions and Industry Payments (https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2830815) Sustainability and Cataract Surgery (https://www.aaojournal.org/article/S0161-6420(25)00135-6/abstract) Relevant Financial Disclosures: Dr. Sridhar is a consultant for Genentech and Regeneron. You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Featuring perspectives from Dr David M O'Malley and Dr Brian M Slomovitz, including the following topics: Ovarian Cancer; HER2-Directed Therapy for Advanced Gynecologic Cancers — Dr O'Malley (0:00) Endometrial Cancer and Cervical Cancer — Dr Slomovitz (23:38) CME information and select publications

Some ambulance crews may not have the best understanding of how a fire crew is going to run a call, with everyone assigned specific roles – often the fire department will be allowing a new crew member to lead the callI always struggled with arriving first on scene on the ambulance because that role is more work and more pressure What does fire like from the ambulance crews when they arrive first?First on scene should be allowed to lead the call and ask for help where needed, second on scene should not be pushing their way in and trying to take over the callSometimes the providers that take over lack experience or are not yet comfortable enough with their own skills to allow someone else to leadIf you have another provider on scene constantly trying to interrupt, give them something to do - often this applies to a disruptive family memberDoes the ambulance paramedic have to attend in the back if the fire paramedic rides in?As a previous ambulance paramedic, I viewed the ambulance as my space, meaning I always appreciated it when the fire paramedic had the respect to treat it as such, asking to ride into the hospital as opposed to telling me they were riding in. As a general rule, if the fire paramedic believes they need to ride in due to acuity, the ambulance paramedic should also attendKash, as a medical director, gives his opinion on this situationI really appreciated it when the fire crews respected our ambulance because the front is truly our officeEMT's can ride in too on low acuity where more hands, not ALS treatment, is neededI've talked before that a paradigm shift is needed for the paramedics at times, where they are more likely to have to attend more calls then their EMT partners -  easy for me to say from outside the field now – but transporting the patient is almost always the safest, lowest liability option, we shouldn't be trying to get out of transports just because it's less workAlways treat the patient like they are a family memberWe are looking for proof that the patient is not sick, as opposed to assuming they are not sick from the outset, our approach is different in emergency medicineWe have, historically, reversed hypoglycemia or opiate OD, and the patient has refused when maybe transport to the hospital is warranted despite the fact that we have temporarily fixed a major problemSupport the showFull show notes can be found here: Episodes - Practical EMS - Content for EMTs, PAs, ParamedicsMost efficient online EKG course here: Practical EKG Interpretation - Practical EMS earn 4 CME and learn the fundamentals through advanced EKG interpretation in under 4 hours. If you want to work on your nutrition, increase your energy, improve your physical and mental health, I highly recommend 1st Phorm. Check them out here so they know I sent you. 1st Phorm | The Foundation of High Performance Nutrition Everything you hear today from myself and my guests is opinion only and doesn't represent any organizations or companies that any of us are affiliated with. The stories you hear have been modified to protect patient privacy and any resemblance to real individuals is coincidental. This is for educational and entertainment purposes only and should not be taken as medical advice nor used to diagnose any medical or healthcare conditions.

Clinical investigators discuss available data guiding the management of gynecologic cancers.  CME information and select publications here.

【

Featuring an interview with Dr John P Leonard, including the following topics: First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00) Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27) Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30) Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24) Practical considerations for the administration of mosunetuzumab (22:03) Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33) Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27) Risk of infection for patients receiving bispecific antibodies (33:23) Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21) Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23) Myths and misperceptions about the management of DLBCL, FL and MCL (47:29) CME information and select publications

Dr John P Leonard from Weill Cornell Medicine in New York, New York, reviews data presented at the 2024 ASH Annual Meeting and their implications for the treatment of non-Hodgkin lymphomas. CME information and select publications here.

On Thursday, Coinbase announced its acquisition of Deribit in a $2.9 billion deal, the largest merger in the crypto industry to date. In this episode, Owen Lau, executive director and senior analyst at Oppenheimer, delves into why Deribit was such a coveted prize, what this deal means for the global derivatives landscape, and how Coinbase is using its position as a public company to cement its dominance. Plus: The importance of Coinbase paying mostly in stock and barely touching its cash How the derivatives market dwarfs spot trading, and is only getting bigger What this means for CME and smaller crypto exchanges And how Base, Coinbase's L2, fits into the long game Visit our website for breaking news, analysis, op-eds, articles to learn about crypto, and much more: unchainedcrypto.com Thank you to our sponsors! FalconX Bitkey: Use code UNCHAINED for 20% off Mantle Guest Owen Lau, Executive Director and Senior Analyst at Oppenheimer Timestamps:

If international tensions break out into a wider war, it is likely to fought differently than previous wars. What will be the same is that the home front will become a target. Instead of Zeppelins, enemy bombers, V2 missiles, or Cuban paratroopers invading, the assault on the home front will likely be cyber warfare -- software viruses and backdoors to take down civilian infrastructure. How would prepping for CyberDoom be different than an EMP or CME?   If you are appreciating these topical episodes, consider becoming a Patron on Patreon, or a monthly member at Buy Me A Coffee, One-time coffee at Buy Me A Coffee are great too! All support appreciated.    

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications

Gemma started her career studying Mechanical Engineering at Cardiff University. She quickly discovered the world of Continuous Improvement and spent 20 years working to improve processes and systems within various manufacturing industries including Automotive, Pharmaceutical, Dairy, Cosmetics & Toiletries, Food, and Medical Devices. She has been a CI Manager numerous times and an Operations Manager running a factory of over 500 people.Gemma is hugely passionate about Improvement and developing people and processes. She gets such a kick out of coaching and facilitating, especially when she sees the lightbulb switch on in someone's head – when they solve a problem; when they realize they have the power to change; or when they get excited about all the improvements they could make.In 2019, Gemma left the world of employment to establish her own business, SPARK Improvement, aiming to switch on as many lightbulbs as possible. Her mission is to help organizations and individuals be the BEST they can be, by helping people SEE, helping people THINK, and helping people CHANGE.Gemma is based in Cheshire in the UK, working globally.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain wrap up their three-part CME series on HER2-positive biliary tract cancer. Joined by Dr. Rachna Shroff, they delved into the critical topic of managing adverse events associated with treatments like TDXD and Zanidatamab. The discussion covered: •⁠  ⁠Overview of the treatment landscape for biliary tract cancer •⁠  ⁠Common side effects of TDXD, including interstitial lung disease, nausea, and fatigue •⁠  ⁠Management strategies for adverse events, including dose reductions and supportive care •⁠  ⁠Insights on Zanidatamab, its side effects, and infusion-related reactions •⁠  ⁠The importance of biomarker testing and patient-centered care in treatment decisions Tune in to gain valuable insights on how to improve patient quality of life while navigating the complexities of HER2-positive biliary tract cancer treatments. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

Special Public Service Announcement – Free Crypto WebinarIn this brief Public Service Announcement, I'm sharing an exciting opportunity for you to join my upcoming free live webinar, “The Case for Cryptocurrency.” This isn't a full podcast episode, but I wanted to let you know about this important event and why it's a must-attend for anyone curious about cryptocurrency or looking to secure their financial future. During the webinar, I'll explain why now is the time to embrace crypto and how it can empower you to stay ahead in a rapidly changing world.Registration is free—just head to preppingacademy.com/crypto to sign up today.Thank you for being part of our community, and I look forward to seeing you at the webinar.Stay safe, and we'll catch up in the next full episode!Join PrepperNet.Net - https://www.preppernet.netPrepperNet is an organization of like-minded individuals who believe in personal responsibility, individual freedoms and preparing for disasters of all origins.Join PrepperNet.Net - https://www.preppernet.netPrepperNet is an organization of like-minded individuals who believe in personal responsibility, individual freedoms and preparing for disasters of all origins.PrepperNet Support the showPlease give us 5 Stars! www.preppingacademy.com Contact us: https://preppingacademy.com/contact/ www.preppernet.net Amazon Store: https://amzn.to/3lheTRTwww.forrestgarvin.com

Featuring perspectives from Prof Rebecca A Dent and Dr Nancy U Lin, including the following topics: Introduction: A New Paradigm for Triple-Positive Breast Cancer? (0:00) CDK4/6 Inhibitors for HR-Positive, HER2-Negative Breast Cancer (10:06) Oral Selective Estrogen Receptor Degraders for HR-Positive, HER2-Negative Breast Cancer (21:17) Treatment of PIK3CA/PTEN/AKT-Mutated Breast Cancer (31:34) Antibody-Drug Conjugates (ADCs) for HR-Positive, HER2-Negative Breast Cancer (38:41) ADCs for HER2-Positive Breast Cancer (46:30) HER2-Targeting Tyrosine Kinase Inhibitors for HER2-Positive Breast Cancer (53:26) ADCs for Advanced Triple-Negative Breast Cancer (58:29) CME information and select publications

The CME's 13th birthday is coming up, and you know what that means: It's pledge month! Now through June 1, GET 50% OFF A NEW MONTHLY OR ANNUAL PATREON SUBSCRIPTION when you use the code CME13 at checkout! Get on it! Join the team! Support the community! Stick it to the man! Belal Muhammad said he doesn't care what you think anymore. He knows he's good, even if you don't. Well, I mean, yeah, he is the UFC welterweight champion, so there is some evidence to suggest he's pretty good. Somehow, though, it still feels like there are constantly a lot of doubts. You doubt he'll win his next fight. You doubt it'll be exciting, if he does. You doubt he'll sell many PPVs, you doubt he'll get in the UFC's good graces, you doubt he'll hang onto that belt for long … and on and on and on … So far, for the most part, he's proved you wrong. Still, that makes this weekend's title defense at UFC 315 against Jack Della Maddalena all the more important. It's the first time in a long while that Belal isn't the underdog. So … gotta win this one, right? Plus, what now for Bo Nickal? That's up to him. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we dive into the environmental and lifestyle factors that impact autoimmunity. From evaluating case reviews to understanding the significance of relationships, stress, and sleep, we explore how these elements shape autoimmune diseases. Discover how proper lifestyle medicine is crucial, and why it's more than just about supplements. Learn about sleep disorders, chemical exposures, and the role of circadian rhythms in modulating the immune system. For more details, visit drknews.com.For patient-oriented courses, visit https://drknews.com/online-courses/For CE and CME practitioner courses, visit https://kharrazianinstitute.com/00:00 Patient Screening and Case Review Process07:55 Sleep's Impact on Immune Function11:27 Rheumatoid Arthritis: Sleep's Vital Role16:15 Stress, Autoimmunity, and IL-17 Dynamics22:13 Exercise & Autoimmunity: Personalized Approach26:57 Chemical Bio-Transformation: Can vs. Can't31:17 Chemical Sensitivity and Immune Response37:45 BPA Study on Autoimmunity Impact44:16 "Identifying Active Heavy Metal Exposure"50:48 Chemical & Immune Tolerance Issues54:42 Avoiding Challenge Tests: Prioritize Immune Reactivity01:01:47 Optimizing Liver Detox and Nutrition01:06:54 Glutathione Protocol for Heavy Metals01:11:03 Glutathione Inhalation for Lung Health01:14:38 Dr. Kharrazian Podcast ResourcesSupport this show http://supporter.acast.com/solving-the-puzzle-with-dr-datis-kharrazian. Hosted on Acast. See acast.com/privacy for more information.

Highlights and Pearls from SHM's Annual Meeting We recap the top pearls for the hospitalist from #SHM #Converge25 hitting updates in GI, stroke, anticoagulation, perioperative medicine, artificial intelligence, and more.  Note: There is no CME for this episode, but visit curbsiders.vcuhealth.org to claim credit for past episodes. Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Care of the Patient Experiencing Homelessness Updates in GI Delirium Adaptive Leadership Transgender Health Capacity Assessment Heart Failure Care of the Transplanted Kidney Precipitated Withdrawal IV contrast Alcohol Withdrawal MRSA Nares Swabs Bugs, Bite, and Fever Perioperative Medicine  Parkinson's Disease Stroke  Outro Credits Producer, Writer, Show Notes: Meredith Trubitt MD, Monee Amin MD, Caroline Coleman MD  Cover Art: Caroline Coleman, MD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Rahul Ganatra, MD MPH Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Michelle Brooks MD, Avital O'Glasser MD, Rahul Ganatra MD MPH Disclosures The Curbsiders report no relevant financial disclosures.  Sponsor: Freed Visit www.getfreed.ai and sse code: CURB50 to get $50 off your first month when you subscribe! Sponsor: Locumstory Learn about locums and get insights from real-life physicians, PAs and NPs at Locumstory.com. Sponsor: Grammarly  Download Grammarly for free at Grammarly.com/PODCAST. Sponsor: Continuing Education Company Special offer for Curbsiders listeners: Save 30% on all online courses and live webcasts with promo code CURB30. Visit www.CMEmeeting.org/curbsiders to explore all offerings and claim your discount.

Dr. Dan Ackerman talks with Dr. Trey Bateman about the significance of blood-based biomarkers in Alzheimer disease. Purchase Annual Meeting On Demand to get access to the recordings and the ability to claim CME through March 1, 2026.  Disclosures can be found at Neurology.org.   

In this episode, hosts Drs. Peter Lu and Jason Silverman talk to Dr. Cary Sauer about Competency-Based Medical Education (CBME) to break down this concept and all the related terminology that is part of this approach to medical training. If you're confused about CBME, EPAs, milestones and competencies, this episode is for you! Dr. Sauer is a Pediatric Gastroenterologist specializing in the care of children with IBD and Division Chief at Children's Healthcare of Atlanta and Emory University.Learning Objectives:Understand what Competency-Based Medical Education (CBME) means and how it differs from traditional time-based models of medical trainingUnderstand how milestones, competencies and EPAs relate to one another within the CBME frameworkRecognize the central role of entrustment and how that can is incorporated into workplace-based assessments of traineesLinks:Pediatric GI Milestones (v2.0)NASPGHAN EPA resourcesABP EPAs for subspecialtiesNorth American Society for Pediatric Gastroenterology,  Hepatology, and Nutrition Position Paper on Entrustable  Professional Activities: Development of Pediatric  Gastroenterology, Hepatology, and Nutrition Entrustable  Professional ActivitiesEducating pediatric gastroenterology fellows: milestones, EPAs, & their application within a new educational curriculumImplementing entrustable professional activities in pediatric fellowships: facilitating the processSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.